EGFR detection from liquid biopsy

Please log in for more information

Please log in for more informationFor sensitive detection of clinically proven somatic mutations in the EGFR oncogene, on cfDNA (circulating-free DNA) extracted from plasma samples

• First companion diagnostic kit based on liquid biopsies
• Compliance with EU IVD Directive 98/79/EC
• Sensitive, robust test that can detect low levels of mutant cfDNA
• Ready-to-use system with simple workflow
• Highly selective and sensitive ARMS and Scorpions PCR technologies
• Kit available January 2015

The therascreen EGFR Plasma RGQ PCR Kit is an in vitro diagnostic test for the detection of exon 19 deletions and exons 20 and 21 substitutions (T790M and L858R respectively) in the EGFR gene and will provide a qualitative assessment of the mutation status.  Results are intended to aid the clinician in identifying patients with non-small cell lung cancer (NSCLC) who may benefit from treatment with IRESSA (gefitinib), from cfDNA extracted from plasma sample when a tissue sample cannot be evaluated. The kit provides all necessary reagents, optimized for rapid and sensitive detection of a low percentage of mutant cfDNA in a background of wild-type cfDNA. ARMS PCR technology combined with the Scorpions detection technology provides exceptionally high sensitivity and specificity for the detection of specific mutations.

Visit product

Visit website